Enhancing Hepatitis C Management: Mortality Trends and Disparities in the US by Sex, Age Group, Race/Ethnicity and Region (1999-2020)
Related Experiment Video
Updated: Jun 27, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sophia Ahmed1, Muhammad Asfandyar Nadir1, Hanzala Ahmed Farooqi2
1Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
Insights
Hepatitis C virus (HCV) mortality in the U.S. increased until 2014, then sharply declined. Significant disparities exist by demographics and region, necessitating targeted interventions for high-risk groups.
Area of Science:
- Public Health
- Epidemiology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection impacts millions in the U.S., causing substantial annual mortality.
- Despite curative treatments developed since 2014, effective strategies for high-risk populations remain critical.
Purpose of the Study:
- To analyze trends in HCV-related mortality in the U.S. from 1999 to 2020.
- To identify demographic and regional disparities in HCV-related deaths.
Main Methods:
- Retrospective analysis of HCV-related deaths using the CDC WONDER database (ICD-10 codes B17.1, B18.2).
- Data stratified by gender, age, race/ethnicity, region, place of death, and urbanisation status.
- Calculated crude and age-adjusted mortality rates; employed joinpoint regression for trend analysis.
Main Results:
- A total of 324,008 HCV-related deaths were reported.
- Overall age-adjusted mortality rate (AAMR) was 4.27 per 100,000.
- Mortality increased until 2014 (APC: 5.00 then 1.95) and declined sharply thereafter (APC: -7.11).
- Males (AAMR: 6.28) and non-Hispanic American Indians (AAMR: 8.72) had higher rates.
- The South region showed the highest AAMR (5.80).
Conclusions:
- HCV-related mortality trends exhibit significant demographic and regional variations.
- Targeted public health interventions are crucial to mitigate HCV burden, especially in vulnerable populations.
Abstract:
Hepatitis C virus (HCV) infection affects approximately 3.9 million people in the United States (U.S.), leading to 8000 to 10,000 deaths annually. Despite advancements in curative treatments since 2014, effective strategies targeting high-risk groups are crucial. This study examines HCV-related mortality trends from 1999 to 2020, focusing on demographic and regional disparities using the CDC WONDER database. A retrospective analysis was conducted using the CDC WONDER database. HCV-related deaths were identified using the International Classification of Diseases, Tenth Revision (ICD-10) codes B17.1 and B18.2. Mortality data were categorised by gender, age, race/ethnicity, region, place of death and urbanisation status. We calculated crude mortality rates (CRs) and age-adjusted mortality rates (AAMRs) per 100,000 population. Joinpoint regression analysis identified significant changes in mortality trends. A total of 324,008 HCV-related deaths were reported. The overall AAMR was 4.27 (95% Confidence Interval [CI]: 4.25 to 4.28). Mortality increased from 1999 to 2014 (1999 to 2007 Annual Percent Change [APC]: 5.00; 2007 to 2014 APC: 1.95) and declined sharply from 2014 to 2020 (APC: -7.11). Males exhibited higher mortality (AAMR: 6.28) than females (AAMR: 2.42). The 55-64 years age group had the highest CR (16.38), while non-Hispanic (NH) American Indians had the highest rate (AAMR: 8.72) among racial groups. Regionally, the South had the highest AAMR (5.80), nearly double that of the West (2.23) and Midwest (2.62). HCV-related mortality trends show significant demographic disparities and regional variations. Targeted interventions are essential to reduce HCV burden, particularly among vulnerable groups.
Related Concept Videos
Retrovirus Life Cycles
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

